Modulating and measuring cellular adhesion
Methods of using compounds having Structure I or the salts or tautomers of the compounds in the treatment of disorders relating to cell adhesion and metastatic processes are presented herein.
1. A method of reducing cellular adhesion in a cancer patient, comprising: administering to the cancer patient a compound of Structure II, a tautomer of the compound, a pharmaceutically acceptable salt of the compound, a pharmaceutically acceptable salt of the tautomer, or a mixture thereof, and measuring the amount of at least one of inducible cell adhesion molecule, vascular cell adhesion molecule, or endothelial leukocyte adhesion molecule in at least a portion of a blood sample withdrawn from the cancer patient after administration of the compound, the tautomer, the pharmaceutically acceptable salt of the compound, the pharmaceutically acceptable salt of the tautomer, or the mixture thereof, wherein cellular adhesion and the levels of circulating adhesion molecules are reduced in the cancer patient after administration, and Structure II has the following formula:
wherein,
A is a group having one of the following Structures:
wherein,
R a is selected from H or straight or branched chain alkyl groups having from 1 to 6 carbon atoms.
2. A method of monitoring the progression of a cancer or cancer treatment in a cancer patient, comprising: measuring the amount of at least one cell adhesion molecule in at least a portion of a blood sample withdrawn from the cancer patient after administration of a compound of Structure II, a tautomer of the compound, a pharmaceutically acceptable salt of the compound, a pharmaceutically acceptable salt of the tautomer, or a mixture thereof to the cancer patient, wherein the cell adhesion molecule is selected from inducible cell adhesion molecule, vascular cell adhesion molecule, or endothelial leukocyte adhesion molecule, and Structure II has the following formula:
wherein,
A is a group having one of the following Structures:
wherein,
R a is selected from H or straight or branched chain alkyl groups having from 1 to 6 carbon atoms.
3. The method of claim 2 , wherein R a is a methyl group, and the compound of Structure II has the Structure IIA having the following formula:
4. The method of claim 3 , wherein the pharmaceutically acceptable salt of the compound of Structure IIA, the pharmaceutically acceptable salt of the tautomer, or the mixture thereof is administered to the cancer patient, and the salt is a lactate salt.
5. The method of claim 2 , wherein R a is a hydrogen, and the compound of Structure II has the Structure IIB having the following formula:
6. The method of claim 2 , wherein R a is a methyl group, and the compound of Structure II has the Structure IIC having the following formula:
7. The method of claim 1 , wherein the amount of at least one of inducible cell adhesion molecule, vascular cell adhesion molecule, or endothelial leukocyte adhesion molecule is reduced in the cancer patient after administration.
8. The method of claim 1 , wherein the amount of a matrix metalloprotease is reduced in the cancer patient after administration.
9. The method of claim 8 , wherein the matrix metalloprotease is matrix metalloprotease-2 or matrix metalloprotease-9.
10. The method of claim 1 , wherein R a is a methyl group, and the compound of Structure II has the Structure IIA having the following formula:
11. The method of claim 10 , wherein the pharmaceutically acceptable salt of the compound of Structure IIA, the pharmaceutically acceptable salt of the tautomer, or the mixture thereof is administered to the cancer patient, and the salt is a lactate salt.
12. The method of claim 1 , wherein the pharmaceutically acceptable salt of the compound of Structure II, the pharmaceutically acceptable salt of the tautomer, or the mixture thereof is administered to the cancer patient, and the salt is a lactate salt.
13. The method of claim 1 , wherein the cancer is selected from the group consisting of bladder cancer, breast cancer, gastrointestinal cancer, ovarian cancer, renal cancer, Hodgkin's lymphoma, and non-Hodgkin's lymphoma.
14. The method of claim 13 , wherein the cancer is breast cancer.
15. The method of claim 2 , wherein the levels of circulating adhesion molecules are reduced in the cancer patient after administration.
16. The method of claim 2 , wherein the amount of at least one of inducible cell adhesion molecule, vascular cell adhesion molecule, or endothelial leukocyte adhesion molecule is reduced in the cancer patient after administration.
17. The method of claim 2 , wherein the cancer is selected from the group consisting of bladder cancer, breast cancer, gastrointestinal cancer, ovarian cancer, renal cancer, Hodgkin's lymphoma, and non-Hodgkin's lymphoma.
18. The method of claim 17 , wherein the cancer is breast cancer.